Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL | Zendy

André Goy | Zendy; Radhakrishnan Ramchandren | Zendy; Nilanjan Ghosh | Zendy; Javier Muñoz | Zendy; David Morgan | Zendy; Nam H. Dang | Zendy; Mark Knapp | Zendy; Maria Delioukina | Zendy; Edwin C. Kingsley | Zendy; Jerry Ping | Zendy; Darrin M. Beaupre | Zendy; Jutta K. Neuenburg | Zendy; Jia Ruan | Zendy

Open Access

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Author(s) -

André Goy,

Radhakrishnan Ramchandren,

Nilanjan Ghosh,

Javier Muñoz,

David Morgan,

Nam H. Dang,

Mark Knapp,

Maria Delioukina,

Edwin C. Kingsley,

Jerry Ping,

Darrin M. Beaupre,

Jutta K. Neuenburg,

Jia Ruan

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2018891598

Subject(s) - ibrutinib , lenalidomide , rituximab , medicine , germinal center , diffuse large b cell lymphoma , refractory (planetary science) , carfilzomib , oncology , lymphoma , b cell , multiple myeloma , immunology , chronic lymphocytic leukemia , leukemia , biology , antibody , astrobiology

The investigators report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed non–germinal center diffuse large B-cell lymphoma (DLBCL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research